All dollar amounts reflected in Canadian dollars unless otherwise stated. VANCOUVER, British Columbia, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-powered drug discovery, today announced its financial results for the three months ended September 30, 2025 (“Q3 2025”), and provided an update on recent corporate developments. Q3 2025 Financial Highlights Reported a net loss ...

Core Viewpoint - Rakovina Therapeutics Inc. reported its Q1 2025 financial results and provided updates on corporate developments, highlighting advancements in AI-powered cancer therapies and strategic financial maneuvers to preserve cash resources [1][5]. Financial Highlights - Cash and cash equivalents stood at $75.8 million, while working capital was negative at $(1.45) million [4]. - The company reported a net loss of $2.18 million, aligning with expectations, with R&D expenses totaling $855,594, reflecting ongoing development of AI-driven drug candidates [5][6]. - General and administrative expenses were $1.22 million, which included costs related to investor relations and exchange fees [5]. - Net cash used in operating activities for the quarter was $1.24 million [5]. Recent Corporate Developments - On May 28, 2025, certain debenture holders opted for common shares instead of cash for interest payments, aiding in cash preservation [5]. - A strategic private placement and convertible debt financing of approximately $4 million was announced on May 15, 2025, with a lead order of $3 million from a strategic investor [5]. - The company plans a 10-for-1 share consolidation, expecting to have around 20 million shares outstanding post-offering [5]. - Dr. David Kideckel was appointed as Chief Financial Officer, pending TSX Venture Exchange approval [5]. - Pre-clinical data for the kt-2000 and kt-5000 programs were presented at the AACR annual meeting, indicating potential alignment with target product profiles [5]. - The company received its first batch of AI-generated ATR inhibitor compounds in collaboration with Variational AI on March 12, 2025 [5]. Share Performance and Market Presence - The company’s common shares were listed on the Frankfurt Stock Exchange under the ticker symbol "7J0" on January 30, 2025 [5]. - The weighted average shares outstanding increased to 140,772,575 from 70,084,925 year-over-year [6].